I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Which has higher valuation & earnings, IMAB or SAGE?

I-Mab has higher earnings, but lower revenue than Sage Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	20.00	-$206.44M	N/A	N/A
Sage Therapeutics	$86.46M	3.56	-$541.49M	-$5.58	-0.90

Do institutionals & insiders hold more shares of IMAB or SAGE?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 5.5% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts recommend IMAB or SAGE?

I-Mab presently has a consensus price target of $8.00, indicating a potential upside of 737.43%. Sage Therapeutics has a consensus price target of $12.89, indicating a potential upside of 156.24%. Given I-Mab's stronger consensus rating and higher probable upside, research analysts plainly believe I-Mab is more favorable than Sage Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sage Therapeutics	2 Sell rating(s)	17 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Does the media favor IMAB or SAGE?

In the previous week, Sage Therapeutics had 3 more articles in the media than I-Mab. MarketBeat recorded 11 mentions for Sage Therapeutics and 8 mentions for I-Mab. I-Mab's average media sentiment score of 0.17 beat Sage Therapeutics' score of -0.19 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sage Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility and risk, IMAB or SAGE?

I-Mab has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Does the MarketBeat Community believe in IMAB or SAGE?

Sage Therapeutics received 572 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 65.52% of users gave Sage Therapeutics an outperform vote while only 64.13% of users gave I-Mab an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 59 64.13%	Underperform Votes 33 35.87%
Sage Therapeutics	Outperform Votes 631 65.52%	Underperform Votes 332 34.48%

Is IMAB or SAGE more profitable?

I-Mab has a net margin of 0.00% compared to Sage Therapeutics' net margin of -317.29%. I-Mab's return on equity of 0.00% beat Sage Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Sage Therapeutics	-317.29%	-50.29%	-45.48%

Summary

I-Mab beats Sage Therapeutics on 11 of the 16 factors compared between the two stocks.